title: [Weight reducing and glucose reducing effects of liraglutide treatment for patients with type 2 diabetes].
abstract: Treatment with glucagon-like peptide-1 analogues including liraglutide is a new treatment option for patients with type 2 diabetes. Treatment with liraglutide decreases HbA1c by 1-2%, and additionally liraglutide has a reducing effect on weight, lipids and blood pressure. Most adverse events are related to the gastrointestinal system and most often they disappear within a few weeks. The risk of major hypoglycaemic episodes is minimal. Long term data on treatment and adverse events with liraglutide are still lacking.
authors.affiliation: Steno Diabetes Center, Niels Steensensvej 2, 2820 Gentofte, Denmark. epenninga@hotmail.com
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Penninga
authors.forename: Kristine
authors.initials: K
authors.lastname: Færch
authors.forename: Thomas
authors.initials: T
authors.lastname: Almdal
mesh_terms: D001786:Blood Glucose / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D000069450:Liraglutide; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D052216:Glucagon-Like Peptide 1; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008055:Lipids; D000069450:Liraglutide